Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The p53 protein integrates multiple upstream signals and functions as a tumor suppressor by activating distinct downstream genes. At the cellular level, p53 induces apoptosis, cell cycle arrest and senescence. A rare mutant form of p53 with the amino acid substitution R175P, found in human tumors, is completely defective in initiating apoptosis but still induces cell cycle arrest. To decipher the functional importance of these pathways in spontaneous tumorigenesis, we used homologous recombination to generate mice with mutant p53-R172P (the mouse equivalent of R175P in humans). Mice inheriting two copies of this mutation (Trp53(515C/515C)) escape the early onset of thymic lymphomas that characterize Trp53-null mice. At 7 months of age, 90% of Trp53-null mice had died, but 85% of Trp53(515C/515C) mice were alive and tumor-free, indicating that p53-dependent apoptosis was not required for suppression of early onset of spontaneous tumors. The lymphomas and sarcomas that eventually developed in Trp53(515C/515C) mice retained a diploid chromosome number, in sharp contrast to aneuploidy observed in tumors and cells from Trp53-null mice. The ability of mutant p53-R172P to induce a partial cell cycle arrest and retain chromosome stability are crucial for suppression of early onset tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cells harboring this mutation (p53P/P) are incapable of activating p53-dependent apoptosis59, but the p53-dependent cellular senescence pathway is intact as induction of telomere dysfunction through overexpression of TRF2-DN in these cells led to dramatic reduction of cellular proliferation and the appearance of senescent cells that stain positive for SA-β-Gal58.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [59]
Experimental — accuracy not yet measuredIn the citing paper
“Mice homozygous for the p.R172P mutation (equivalent to the human p.R175P alteration) exhibit defects in TP53‐dependent apoptosis but retain a partial cell cycle checkpoint function [44].”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321 · cited 1×
“p53-R172P weakly induced Cdkn1a (encoding p21), a crucial target of p53 in cell cycle contro”
Backgroundp53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“gif" NDATA ITEM> ]> The p53 protein integrates multiple upstream signals and functions as a tumor suppressor by activating distinct downstream gene”
BackgroundMice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · cited 1×
“Trp53 -null mice succumb to early tumorigenesis, predominantly thymic lymphoma”
Backgroundp53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864 · cited 1×
“To confirm this finding, we measured apoptosis in freshly isolated thymocytes after γ-radiatio”
Ko, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344 · cited 1×
“gif" NDATA ITEM> ]> The p53 protein integrates multiple upstream signals and functions as a tumor suppressor by activating distinct downstream gene”
BackgroundThymocyte apoptosis induced by p53-dependent and independent pathways
Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., & Wyllie, A. H. (1993) · Nature · doi:10.1038/362849a0 · Cited by 2,271
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051 · cited 1×
“Trp53 -null mice succumb to early tumorigenesis, predominantly thymic lymphoma”
BackgroundGenetic instability in colorectal cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/386623a0 · Cited by 1,986 · cited 1×
“Genomic instability promotes tumorigenesis in multiple setting”
Cited by
Items 201–300 of 324
Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo
Slee, E. A., Benassi, B., Goldin, R. D., Zhong, S., Ratnayaka, I., Blandino, G., & Lü, X. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005165107 · Cited by 27
“This rarity may be due to the relatively rapid onset of other tumor types that mask the participation of the p53/p21 pathway in liver tumorigenesis (15, 18, 23, 26).”
Backgroundp53 in breast cancer: mutation and countermeasures
Kumar, S. R., Walia, V., Ray, M., & Elble, R. C. (2007) · Frontiers in bioscience · doi:10.2741/2378 · Cited by 24
Gurunathan, S., & Kim, J. (2018) · Nanomaterials · doi:10.3390/nano8060396 · Cited by 24
“It can bind the anti-apoptotic Bcl-2 proteins (Bcl-2 and Bcl-x) and can activate the pro-apoptotic multidomain proteins (Bax and Bak) to induce cytochrome C release and subsequent apoptosis [74].”
BackgroundPermission to pass: on the role of p53 as a gatekeeper for aneuploidy
Marques, J. F., & Kops, G. J. P. L. (2023) · Chromosome Research · doi:10.1007/s10577-023-09741-9 · Cited by 29
“Mouse embryonic fibroblasts lacking p53 have amplified centrosomes, as a result of misregulated CDK2/ cyclin-E compromising the centrosome duplication cycle (Fukasawa et al. 1996; Liu et al. 2004; Tara-pore et al. 2001).”
BackgroundConstitutive and induced functions of the p53 gene
Zheltukhin, A. O., & Chumakov, P. M. (2010) · Biochemistry (Moscow) · doi:10.1134/s0006297910130110 · Cited by 33
Functional relationship between p53 and RUNX proteins
Bae, S., Kolinjivadi, A. M., & Ito, Y. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy076 · Cited by 22
Partial p53 reactivation is sufficient to induce cancer regression
Klimovich, B., Meyer, L., Merle, N., Neumann, M. M., König, A. M., Ananikidis, N., Keber, C. U., Elmshäuser, S., Timofeev, O. N., & Stiewe, T. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02269-6 · Cited by 23
Li, X., Wu, L.-M., Zopp, M., Kopelov, S., & Du, W. (2019) · Stem Cells · doi:10.1002/stem.3015 · Cited by 20
Regulation of p53-dependent transcription
Jõers, A. (2004) · DSpace repository (University of Tartu) · Cited by 248
Conquering the complexity of p53
Attardi, L. D., & DePinho, R. A. (2003) · Nature Genetics · doi:10.1038/ng0104-7 · Cited by 19
IL-7Rα deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis
Kibe, R., Zhang, S., Guo, D., Marrero, L., Tsien, F., Rodríguez, P. C., Khan, S., Zieske, A. W., Huang, J., Li, W., et al. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2011.203 · Cited by 19
“In sharp contrast, translocations in tumors from p53 mice were very rare and none of the metaphases contained two or more translocations per cell (Figure 4b), similar to previous reports.(20,21) To further explore other chromosome aberrations in the thymic lymphomas, we employed spectral karyotyping (SKY) analyses.”
BackgroundResultSphingolipids and the link between alcohol and cancer
Barron, K. A., Jeffries, K. A., & Krupenko, N. I. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109058 · Cited by 23
p21WAF1/CIP1 may be a tumor suppressor after all
Gartel, A. L. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.8.4712 · Cited by 19
A novel Ku70 function in colorectal homeostasis separate from nonhomologous end joining
Puebla‐Osorio, N., Kim, J. J., Ojeda, S. S., Zhang, H., Tavana, O., Li, S., Wang, Y., Ma, Q., Schluns, K. S., & Zhu, C. (2013) · Oncogene · doi:10.1038/onc.2013.234 · Cited by 18
Olszewski, M. B., Pruszko, M., Snaar-Jagalska, E. B., Żylicz, M., & Żylicz, M. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4723 · Cited by 25
“Notably, no such increase was observed in otherwise genetically identical mice with the p53+/R172P genotype, which reflects a less common mutation observed in humans (17).”
BackgroundHow Does Cellular Senescence Prevent Cancer?
Lynch, M. (2006) · DNA and Cell Biology · doi:10.1089/dna.2006.25.69 · Cited by 19
Lysines in the tetramerization domain of p53 selectively modulate G1 arrest
Beckerman, R., Yoh, K. E., Mattia-Sansobrino, M., Zupnick, A., Laptenko, O., Karni-Schmidt, O., Ahn, J., Byeon, I. L., Keezer, S. M., & Prives, C. L. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1170270 · Cited by 20
“In fact, mouse studies have conflictingly suggested that p53’s arrest or apoptotic functions are individually dispensable for tumor suppression.(54,55) Mechanisms underlying this decision making process could be as simple as levels of p53 protein, presumably dictated by the extent of cellular stress,(32) or as complex…”
BackgroundTimofeev, O. N., & Stiewe, T. (2021) · Cancers · doi:10.3390/cancers13102422 · Cited by 19
“Genetically modified mouse models were therefore successfully used for studying p53 functions and consequences of its inactivation in cancer [84].”
Expanding the reach of the p53 tumor suppressor network
Zambetti, G. P. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.13 · Cited by 17
Storti, F. (2008) · Cited by 16
Biophysical investigation of the dual binding surfaces of human transcription factors FOXO4 and p53
Kim, J., Ahn, D., & Park, C. (2021) · FEBS Journal · doi:10.1111/febs.16333 · Cited by 15
Heerema, N. A., Muthusamy, N., Zhao, Q., Ruppert, A. S., Breidenbach, H., Andritsos, L. A., Grever, M. R., Maddocks, K. J., Woyach, J. A., Awan, F. T., et al. (2020) · Haematologica · doi:10.3324/haematol.2018.212571 · Cited by 17
Kashimoto, N., Hayama, M., Kamiya, K., & Watanabe, H. (2006) · Oncology Reports · doi:10.3892/or.16.6.1181 · Cited by 14
“A recent study has shown that for the prevention of tumor formation it is important to arrest the apoptosis guidance ability of p53 and the destabilization of the genome, and the destabilized prevention of a genome may be attained by the guidance of a cell cycle stop (23).”
Mutant p53 Gain-of-Function in the Spotlight: Are We Suffering a GOF Delusion?
Lane, D. P. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1362 · Cited by 15
Lin, S., Yu, L., Yang, J., Liu, Z., Karia, B., Bishop, A. J. R., Jackson, J. G., Lozano, G., Copland, J. A., Mu, X., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.265397 · Cited by 14
Self-citationZhou, L., Zeng, Y., Liu, Y., Du, K., Luo, Y., Dai, Y., Pan, W., Zhang, L., Zhang, L., Tian, F., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12234-5 · Cited by 12
“…induces several cell activities including apoptosis, cell cycle arrest, and senescence in cells and plays an essential role in controlling various metabolic pathways, which are responsible for maintaining cellular metabolic homeostasis and enabling cells to effectively respond to stressors [9, 10].”
BackgroundHu, S., Ouyang, J., Zheng, G., Lu, Y., Zhu, Q., Wang, B., Ye, L., & Zhu, C. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.05.046 · Cited by 13
B‐cell linker protein prevents aneuploidy by inhibiting cytokinesis
Kamino, H., Futamura, M., Nakamura, Y., Kitamura, N., Kabu, K., & Arakawa, H. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00990.x · Cited by 12
Muñoz, N. M., Katz, L. H., Shin, J., Gi, Y. J., Menon, V. K., Gagea, M., Rashid, A., Chen, J., & Mishra, L. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.32 · Cited by 12
“Genetically engineered mice prone to T-cell lymphoma such Eμ-tTA/tetO-MYC [12], Trp53-/- [13] and Lck-Tert [14] have also been generated.”
BackgroundKu70 Functions in Addition to Nonhomologous End Joining in Pancreatic β-Cells
Tavana, O., Puebla‐Osorio, N., Kim, J., Sang, M., Jang, S., & Zhu, C. (2013) · Diabetes · doi:10.2337/db12-1218 · Cited by 12
Analysis of p53 Gene Alterations in Cancer: A Critical View
Soussi, T. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_12 · Cited by 20
Sarkar, J., Domínguez, E. R., Li, G., Kusewitt, D. F., & Johnson, D. G. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22019 · Cited by 11
“Malfunction of the p53 pathway is an almost universal hallmark of human cancers, although the relative importance of the different p53 activities for tumor suppression is a matter of debate [1,2].”
BackgroundZhao, L., Wang, B., Zhao, X., Wu, X., Zhang, Q., Wei, C., Shi, M.-L., Li, Y., Tang, W., Zhang, J., et al. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22737 · Cited by 12
“For example, the R172Pmutant protein has lost the function of regulating apoptosis but remains partially functional in regulating cell cycle arrest, and the mice bearing this mutation retain chromosome stability and show late onset tumorigenesis.(14) Most studiesare focusedontheabovementionedhot-spotmutations, which h…”
BackgroundUnusually stable abnormal karyotype in a highly aggressive melanoma negative for telomerase activity
Gagos, S., Papaioannou, G., Chiourea, M., Merk-Loretti, S., Jefford, C.-E., Mikou, P., Irminger‐Finger, I., Liossi, A., Blouin, J., & Dahoun, S. P. (2008) · Molecular Cytogenetics · doi:10.1186/1755-8166-1-20 · Cited by 10
“It is interesting that although p53 deficiency has been related to increased rates of numerical chromosome instability or polyploidy [22], in this melanoma hemizygosity of p53 was not associated with continuous genomic instability.”
BackgroundValent, L., & Strasser, A. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.8.3 · Cited by 14
“Given the critical roles of apoptosis, G1-S boundary cell cycle arrest and senescence in the p53-regulated responses to acute DNA damage in non-transformed cells, it has been widely proposed that these same processes must also be essential for p53-mediated tumour suppression [26, 140, 153].”
BackgroundSTAT5A is regulated by DNA damage via the tumor suppressor p53
Mukhopadhyay, U. K., Cass, J., Raptis, L. H., Craig, A. W., Bourdeau, V., Varma, S., Sengupta, S., Elliott, B. E., & Ferbeyre, G. (2016) · Cytokine · doi:10.1016/j.cyto.2016.01.013 · Cited by 12
Hainaut, P. L., Wiman, K. G., & Olivier, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8 · Cited by 10
Treisman, D. M., Li, Y., Pierce, B. R., Li, C., Chervenak, A. P., Tomasek, G. J., Lozano, G., Zheng, X., Kool, M., & Zhu, Y. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz027 · Cited by 9
Self-citationDisruption of tp53 leads to cutaneous nevus and melanoma formation in Xenopus tropicalis
Ran, R., Li, L., Shi, Z., Liu, G., Jiang, H., Fang, L., Xu, T., Huang, J., Chen, W., & Chen, Y. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13301 · Cited by 7
Self-citationThe non-homologous end-joining activity is required for Fanconi anemia fetal HSC maintenance
Nie, Y., Li, Y., Li, X., Wilson, A. F., & Pang, Q. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1206-0 · Cited by 8
The telomere complex and the origin of the cancer stem cell
Torres-Montaner, A. (2021) · Biomarker Research · doi:10.1186/s40364-021-00339-z · Cited by 9
The Molecular Biology of Cancer
Tobias, E. S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00021-5 · Cited by 8
Sgura, A., Amicis, A. D., Stronati, L., Cinelli, S., Pacchierotti, F., & Tanzarella, C. (2008) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20405 · Cited by 8
“The capacity to maintain chromosome stability was shown to be sufficient for the tumour suppression function of p53 [Liu et al., 2004].”
Targeted Degradation of Mutant p53 Reverses the Pro-oncogenic Dominant-Negative Effect
Gencel‐Augusto, J., & Lozano, G. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1054 · Cited by 7
Self-citationLemon, J. A., Taylor, K., Verdecchia, K., Phan, N., & Boreham, D. R. (2014) · Dose-Response · doi:10.2203/dose-response.14-008.lemon · Cited by 7
“As a biomarker of genetic instability, micronucleated reticulocytes (MN-RETs) are indicative of chromosome damage in bone marrow progenitor cells, which appears to be an important contributor to tumorigenesis in p53-deficient mice (Symonds et al. 1994, Liu et al. 2004).”
Marney, C. B., Anderson, E. S., Baum, R., & Schmitt, A. M. (2022) · Cells · doi:10.3390/cells11111818 · Cited by 7
“A similarly delayed onset of tumor formation and shift in tumor spectrum has been observed in various knock-in p53 mutant mice strains, including p53S23A/S23A [50] and p53R172P/R172P [51].”
BackgroundProtéger et sévir : p53, métabolisme et suppression tumorale
Albagli, O. (2015) · médecine/sciences · doi:10.1051/medsci/20153110013 · Cited by 10
Mouse Models of Frequently Mutated Genes in Acute Myeloid Leukemia
Mohanty, S., & Heuser, M. (2021) · Cancers · doi:10.3390/cancers13246192 · Cited by 6
Wang, B., Dan, J., Li, H., Hou, J. Y., Shi, M., Singh, S. K., Chang, J. T., & Luo, Y. (2018) · FEBS Letters · doi:10.1002/1873-3468.13223 · Cited by 6
Lu, X., Yang, C., Yin, C., Dyke, T. V., & Simin, K. J. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0277 · Cited by 6
“In the lymphoma model, Bcl-2 overexpressing tumors advance to a phenotype that is morphologically indistinguishable from p53-deficient tumors, indicating that apoptosis alone is sufficient for tumor progression (10), even though others have shown nonapoptotic p53 functions also contribute to lymphoma tumor suppression…”
BackgroundWalters, K. (2006) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2006.09.028 · Cited by 6
Malkin, D. M. (2009) · Springer eBooks · doi:10.1007/978-0-387-77236-3_11 · Cited by 6
Nault, J., & Zucman‐Rossi, J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.03.010 · Cited by 5
Jaylet, T., Chauhan, V., Mezquita, L., Boroumand, N., Laurent, O., Elihn, K., Lundholm, L., Armant, O., & Audouze, K. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1571290 · Cited by 7
Lone, W., Yu, J., Liu, X., Jochum, D. T., Bouska, A. C., Shetty, K., Herek, T. A., Sharma, S., Bi, C., Shah, A. R., et al. (2025) · Science Advances · doi:10.1126/sciadv.adx6877 · Cited by 5
“Whereas mice with Pten deletions ( 18 ) and Trp53 deletions ( 19 , 20 ) spontaneously develop T-ALL, mice with Trp53 deletion develop cytotoxic TCL with a CD1d-restricted natural killer (NK)/T cell of origin ( 21 ) and a transcriptomic program similar to human hep-atosplenic T cell lymphoma (HSTCL)…”
Splicing DNA Damage Adaptations for the Management of Cancer Cells
Singh, A. K., Yadav, D., & Malviya, R. (2023) · Current Gene Therapy · doi:10.2174/0115665232258528231018113410 · Cited by 4
Mis-splicing drives loss of function of p53E224D point mutation
Lock, I. C., Leisenring, N. H., Floyd, W., Xu, E. S., Luo, L., Ma, Y., Mansell, E. C., Cardona, D. M., Lee, C., & Kirsch, D. G. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318856 · Cited by 3
“The p53 R175P/R175P and the p53 E177R/E177R mice display a delayed onset of tumorigenesis relative to p53 -/- [16,17].”
The function of a heterozygous p53 mutation in a Li-Fraumeni syndrome patient
Li, Y., Li, T., Tang, Y., Zhan, Z., Ding, L., Song, L., Yu, T., Yang, Y., Ma, J., Zhang, Y., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234262 · Cited by 4
Ibusuki, R., Iwama, E., Shimauchi, A., Kawano, H., Tsuneoka, Y., Hashisako, M., Harada, T., Tsuchiya‐Kawano, Y., Nakatomi, K., Furuyama, K., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108018 · Cited by 3
p53’s Dilemma in Transcription: Analysis by Microarrays
Kannan, K., Rechavi, G., & Givol, D. (2010) · Molecular biology intelligence unit · doi:10.1007/978-1-4419-8231-5_10 · Cited by 3
Campisi, J. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.04.015 · Cited by 5
“First, mice in which wild-type p53 was replaced by a mutant protein that can induce cell-cycle arrest, but not apoptosis, in response to acute damage or stress retained substantial protection from spontaneous tumorigenesis (Liu et al., 2004).”
BackgroundiPSCs are transcriptionally and post-transcriptionally indistinguishable from fESCs
Wang, Y. (2011) · Frontiers in bioscience · doi:10.2741/4011 · Cited by 3
De la mesure en toute chose : dérégulation de p53, cancer et syndromes télomériques
Jaber, S., Simeonova, I., & Toledo, F. (2013) · médecine/sciences · doi:10.1051/medsci/20132912003 · Cited by 6
“Par exemple, la plupart des souris exprimant des p53 mutantes dont l’activité est réduite, mais non nulle (p53R172P ou p53ΔP), développent des tumeurs dans la deuxième année de leur vie [11, 12].”
BackgroundAging or tumor: the crosstalk between telomerase and p53
Zhang, X., Tang, W., & Luo, Y. (2009) · Hereditas (Beijing) · doi:10.3724/sp.j.1005.2009.00451 · Cited by 3
Škunca, Ž. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.87241 · Cited by 4
Sage, J., Attardi, L. D., & Dyke, T. V. (2011) · Springer eBooks · doi:10.1007/978-0-387-69805-2_14 · Cited by 3
Inflammation, necrosis, and cancer
Lotze, M. T. (2004) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7861-6_9 · Cited by 3
Oncogenic potential of BRAF versus RAS
Benjamin, C. L., & Ananthaswamy, H. N. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.10.033 · Cited by 3
CEP-1 is pro-choice for reproductive health in C. elegans
Mateo, A.-R. F., & Derry, W. B. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1204862 · Cited by 3
“mice develop tumors much earlier in life and exhibit chromosomal abnormalities, which were initially attributed to p53s role in centrosome duplication.(7) Alternatively, the chromosome deletions and translocations observed in these mice may be due to a role for p53 in suppressing NHEJ, similar to what we found with CE…”
ResultArachidonoylethanolamide promotes cellular senescence in a human glioblastoma cell line
Zapi-Colín, L. Á., Dotor-Hernández, J. E., Contreras, I., & Estrada, J. A. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.151235 · Cited by 2
Chen, H., Guo, Z., Li, P., Liao, W., Li, Y., Li, B., Li, Y., Zhu, Q., Lu, Y., Huang, L., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-12522-5 · Cited by 2
“The R175P mutant, a mutation at the same site in TP53, functions in a completely different way, retaining the capability to arrest the cell cycle, but losing the ability to induce apoptosis 11 .”
Mutant p53-Driven Tumorigenesis
Terzian, T., & Lozano, G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_5 · Cited by 2
Self-citationThe protective effect of arrest
Greenwood, E. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1284 · Cited by 2
Mutagenesis in vivo in T cells of p21-deficient mice
Shao, C., Liang, L., Zhao, X., Chen, Y., Zheng, B., Chen, J., Luo, M., & Tischfield, J. A. (2009) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2009.09.001 · Cited by 2
“While it has been firmly established that loss or mutation of p53 can lead to a broad spectrum of human malignancy, it remains controversial which of the p53regulated pathways, or a combination of them, functions as a tumor-suppressing mechanism [2,3].”
Grady, W. M., & Carethers, J. M. (2008) · Cited by 2
Hypoxia inducible factor 1α-driven steroidogenesis impacts systemic hematopoiesis
Watts, D., Eberz, N., Jaykar, M. T., Sinha, A. N., Ermis, C., Tiebel, J., Baschant, U., Rauner, M., Grinenko, T., Chavakis, T., et al. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00777-9 · Cited by 1
“As an enhancer of p53 signaling, Trp53bp2 promotes cell cycle arrest and maintains genomic stability [32], potentially preventing HSCs from entering an active proliferative state.”
Rodriguez, L., Leroy, B., Toledo, F., Funk, J. S., Stiewe, T., Baliakas, P., Delhommeau, F., & Soussi, T. (2026) · npj Genomic Medicine · doi:10.1038/s41525-026-00568-x · Cited by 2
“…that result in either a reduced global loss of protein activity or a function-speci fi c defect. p53 p.R175P was the fi rst variant showntohaveheterogeneouslossofactivity,asitretainstheabilitytoinduce cellcyclearrestbutlosesthecapacitytotriggerapoptosis,andisless tumorigenicinanimalmodels 9 – 11 .”
p53: Point Mutations, SNPs and Cancer
Fang, M., Simeonova, I., & Toledo, F. (2012) · InTech eBooks · doi:10.5772/33715 · Cited by 2
“indicated that apoptosis is not the only p53-dependent cellular response essential for tumour suppression, and that the maintenance of chromosomal stability is also important (Liu et al., 2004).”
BackgroundHartwig, F. P. (2013) · Journal of Bone Marrow Research · doi:10.4172/2329-8820.1000123 · Cited by 1
“In another study, Trp53P/P mice showed susceptibility to lymphomas not significantly different than Trp53P/+ animals (while Trp53P/P/Terc+/- and Trp53P/+/Terc+/genotypes conferred susceptibility, and Trp53P/P/Terc-/- and Trp53P/+/ Terc-/- genotypes conferred resistance) [24].”
BackgroundModeling osteosarcoma: in vitro and in vivo approaches
Walkley, C. R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00017-0 · Cited by 3
The Genomics of Liposarcoma: A Review and Commentary
Beird, H. C., Lazar, A. J., & Truong, D. D. (2022) · Global Journal of Human Social Science · doi:10.34257/gjsfrgvol22is2pg15 · Cited by 1
Pancreatic β-Cell Senescence: A Contributor to Type 2 Diabetes
Urmi, R., Singh, R., Singh, M., & Sinha, B. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-1041-9_8 · Cited by 1
Fagherazzi, P., Stixová, L., & Bártová, E. (2025) · European Biophysics Journal · doi:10.1007/s00249-025-01774-8 · Cited by 3
“…functions of p53 has been challenged by pivotal studies showing that certain p53 mutants, despite lacking the ability to transcriptionally regulate cell cycle and/or apoptosis, still retain tumor suppressor activity (Cosme-Blanco et al. 2007; Li et al. 2012; Liu et al. 2004; Valente et al. 2013).”
Lessons on p53 from Mouse Models
Jiang, D., & Attardi, L. D. (2010) · Molecular biology intelligence unit · doi:10.1007/978-1-4419-8231-5_2 · Cited by 1
Molecular Targets of Green Tea Catechin, EGCG, on Human Colorectal Carcinogenesis
Sukhthankar, M. (2009) · Cited by 1
Role of TP53 Mutations in Cancer (An Overview)
Toledo, F. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8442-3_5 · Cited by 2
“In striking contrast, the R175P mutation is rare in human cancers, consistent with the observation that the murine p53R172P mutant retains partial tumor-suppressive functions (Liu et al., 2004).”
BackgroundSenescence, Apoptosis, and Cancer
Dimri, M., & Dimri, G. P. (2016) · Springer eBooks · doi:10.1007/978-1-59745-458-2_10 · Cited by 1
IL-7R{alpha} deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis
Cui, Y. R., Kibe, R., Zhang, S., Guo, D., Marrero, L., Tsien, F., Rodríguez, P. C., Zieske, A. W., Huang, J., Li, W., et al. (2012) · The Journal of Immunology · Cited by 1
The BH3‐only Proteins Puma and Noxa: Two Brothers in Arms
Erlacher, M., Michalak, E. M., Strasser, A., & Villunger, A. (2006) · Wiley eBooks · doi:10.1002/9783527619665.ch13 · Cited by 1
Mecucci, C., Battista, V. D., & Nofrini, V. (2016) · Wiley eBooks · doi:10.1002/9781118527948.ch1 · Cited by 1
P53 Links Tumor Development to Cancer Therapy
Hemann, M. T., & Lowe, S. W. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_15 · Cited by 2
“Germline knock-in mice expressing a tumor-derived p53 mutant identified a distinct set of p53 effector functions essential for T cell tumor suppression ( Liu et al., 2004 ).”
BackgroundReplicative Senescence as an Intrinsic Tumor-Suppressor Mechanism
Chang, S. S. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1075-2_8
Self-citationGenomic Instability and DNA Repair
Gagos, S. (2007) · Wiley eBooks · doi:10.1002/9780470025079.chap07.pub2
THE CONSEQUENCES OF DISRUPTING THE MDM2-P53 BALANCE IN HEMATOPOIESIS
Abbas, H. A. (2010) · Digital Commons-TMC (Texas Medical Center)
Wig-1: A p53 target that regulates the mRNA of p53 and Myc - and more?
Vilborg, A. (2010) · Figshare
The Biological Effects of PET Scans with 18F-FDG in Mice
Taylor, K. (2011) · MacSphere (McMaster University) · doi:10.71548/12042
Expression and function of the small immune adaptor protein SAP
Nagy, N. (2006) · Figshare
Gain‐of‐Function Mutants of p53 and Their Role in Tumourigenesis
Vaughan, C. A., Deb, S. P., & Deb, S. (2014) · Wiley eBooks · doi:10.1002/9780470015902.a0022449
Models of signal transduction in cancer
Li, D., & Li, S. (2007) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2007.11.001
TRANSCRIPTOME STUDIES OF CELL-FATE AND AGING
Larsson, O. S. (2005) · Figshare
Metadata
- Authors
- Liu, G., Parant, J. M., Lang, G., Chau, P., Chavez-Reyes, A., El-Naggar, A. K., Multani, A., Chang, S., & Lozano, G.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Lozano, Guillermina
- Venue
- Nature Genetics
- Published
- 2003-12-21
- Volume
- 36
- Issue
- 1
- Pages
- 63-68
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1970378023
- Cited by
- 325
- References
- 30
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 6 · 2023: 3 · 2022: 7 · 2021: 8 · 2020: 12 · 2019: 15 · 2018: 9 · 2017: 11 · 2016: 16 · 2015: 5 · 2014: 15 · 2013: 18 · 2012: 19
- FWCI
- 10.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Kadoorie Charitable Foundation
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- p53, chromosome stability, apoptosis, tumor suppression, spontaneous tumor development, thymic lymphoma, sarcoma, aneuploidy, cell cycle arrest, senescence, diploidy
- MeSH terms
- Animals, Cell Cycle, Lymphoma, Mice, Mutant Strains, Ploidies, Genes, p53, Apoptosis, Chromosomal Instability, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.